Novel approach for attenuation of pirfenidone-induced digestive symptoms: a respirable powder formulation of pirfenidone / Yoshiki Seto, Gen Suzuki, Asako Aoki, Yuuki Kaneko, Masashi Kato, Hideyuki Sato, Satomi Onoue
Aim:Orally taken pirfenidone (PFD) often causes digestive symptoms. A respirable powder formulation of PFD (PFD-RP) was previously developed, and this study aimed to verify the risk of digestive symptoms after insufflation of PFD-RP.Materials & methods:Intestinal motility and gastrointestinal exposure levels was evaluated in PFD-RP (0.3-mg PFD/rat: a pharmacologically effective dose) and orally taken PFD (10–100 mg/kg) groups.Results & conclusion:Orally taken PFD at doses above 30 mg/kg significantly inhibited intestinal motility. In contrast, insufflated PFD-RP led to comparable intestinal motility in control group, and gastrointestinal exposure levels in PFD-RP group were markedly lower than those in orally taken PFD groups. Inhalation therapy using PFD-RP may be efficacious to reduce the risk of digestive symptoms frequently induced by orally taken PFD. Aim: Materials & methods: Results & conclusion.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
Erscheinungsort nicht ermittelbar: 2021 |
| Enthalten in: |
|---|
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Seto, Yoshiki [VerfasserIn] |
|---|
| Links: |
FID Access [lizenzpflichtig] |
|---|
| Themen: |
Digestive symptoms |
|---|
| Umfang: |
1 Online-Ressource (8 p) |
|---|
| doi: |
10.4155/tde-2021-0027 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
KFL011092327 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | KFL011092327 | ||
| 003 | DE-627 | ||
| 005 | 20230713210627.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 230609s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.4155/tde-2021-0027 |2 doi | |
| 035 | |a (DE-627)KFL011092327 | ||
| 035 | |a (KFL)prod_FICIBQ_10.4155/tde-2021-0027 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 084 | |a PHARM |q DE-84 |2 fid | ||
| 100 | 1 | |a Seto, Yoshiki |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Novel approach for attenuation of pirfenidone-induced digestive symptoms: a respirable powder formulation of pirfenidone |c Yoshiki Seto, Gen Suzuki, Asako Aoki, Yuuki Kaneko, Masashi Kato, Hideyuki Sato, Satomi Onoue |
| 264 | 1 | |a [Erscheinungsort nicht ermittelbar] |c 2021 | |
| 300 | |a 1 Online-Ressource (8 p) | ||
| 336 | |a nicht spezifiziert |b zzz |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 520 | |a Aim:Orally taken pirfenidone (PFD) often causes digestive symptoms. A respirable powder formulation of PFD (PFD-RP) was previously developed, and this study aimed to verify the risk of digestive symptoms after insufflation of PFD-RP.Materials & methods:Intestinal motility and gastrointestinal exposure levels was evaluated in PFD-RP (0.3-mg PFD/rat: a pharmacologically effective dose) and orally taken PFD (10–100 mg/kg) groups.Results & conclusion:Orally taken PFD at doses above 30 mg/kg significantly inhibited intestinal motility. In contrast, insufflated PFD-RP led to comparable intestinal motility in control group, and gastrointestinal exposure levels in PFD-RP group were markedly lower than those in orally taken PFD groups. Inhalation therapy using PFD-RP may be efficacious to reduce the risk of digestive symptoms frequently induced by orally taken PFD. Aim: Materials & methods: Results & conclusion | ||
| 653 | |a digestive symptoms | ||
| 653 | |a gastrointestinal motility | ||
| 653 | |a inhalation | ||
| 653 | |a pirfenidone | ||
| 653 | |a pulmonary fibrosis | ||
| 700 | 1 | |a Suzuki, Gen |e verfasserin |4 aut | |
| 700 | 1 | |a Aoki, Asako |e verfasserin |4 aut | |
| 700 | 1 | |a Kaneko, Yuuki |e verfasserin |4 aut | |
| 700 | 1 | |a Kato, Masashi |e verfasserin |4 aut | |
| 700 | 1 | |a Sato, Hideyuki |e verfasserin |4 aut | |
| 700 | 1 | |a Onoue, Satomi |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Therapeutic Delivery |d London : Future Science, 2010 |h Online-Ressource |w (DE-627)KFL000006173 |w (DE-600)2590688-4 |w (DE-576)398101612 |x 2041-6008 |7 nnns |
| 856 | 4 | 0 | |u http://pharmazie.proxy.fid-lizenzen.de/fid/future-medicine-ejournals-pharmazie/doi.org/10.4155/tde-2021-0027 |m X:KFL |x Resolving-System |y FID Access |z lizenzpflichtig |
| 912 | |a GBV_KFL | ||
| 912 | |a FID-PHARM | ||
| 935 | |i IMPORT_0628_prod_FICIBQ_03 | ||
| 951 | |a AR | ||